Meet us at…
Latest news
OTR3 is proud to share a recent publication in the “Aesthetic Surgery Journal Open Forum” from the Oxford University Press concerning “a retrospective self-controlled study evaluating the Prophylactic Effects of our Medical Device Cacipliq 20 on Postsurgical scars.” https://doi.org/10.1093/asjof/ojad031 Aesthetic Surgery Journal Open Forum (ASJOF) is an international award-winning, peer-reviewed, [...]
11 April 2023
OTR3 announces first patient enrollment in its pivotal study “MATRISCAR”, a double blind placebo-controlled study aimed at demonstrating the effects of CACIPLIQ20 on Post-surgical Scars
26 January 2023
Cacipliq 20® - Diabetic Foot Ulcer Matrix Protection Therapy in Diabetic Foot Ulcers: Pilot Study of CACIPLIQ20® INES SLIM (MD), HOUDA TAJOURI (MD), DENIS BARRITAULT (PHD), MAHA KACEM NJAH (MD), KOUSSAY ACH (MD), MOLKA CHADLI CHAIEB MD, LARBI CHAIEB (MD) We evaluated whether matrix protection therapy by Cacipliq 20® [...]
15 February 2019
Cacipliq 20® - Foot Ulcer Efficacy of a New Heparan Sulfate Mimetic Dressing in the Healing of Foot and Lower Extremity Ulcerations in Type 2 Diabetes: A Case Series Nikolaos Papanas, Costas Demetzos, Natassa Pippa, Efstratios Maltezos and Nicholas Tentolouris A novel heparan sulfate glycosaminoglycan mimetic product for local [...]
15 February 2019
Cacipliq 20® - hand injury ReGeneraTing Agents (RGTA®) are a new option to improve amputation outcomes in the recovery of severe hand injuries Roohi Sharifah Ahmad and Denis Barritault Cacipliq 20® was used to accelerate the healing process and stimulate the viability of flaps and skin grafts, thereby improving [...]
15 February 2019
